Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:RNANASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeRNAAvidity Biosciences$29.15-0.5%$30.51$21.51▼$56.00$3.53B0.951.39 million shs991,187 shsSRPTSarepta Therapeutics$18.87-6.0%$42.38$18.30▼$168.31$1.97B0.612.06 million shs6.91 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceRNAAvidity Biosciences0.00%-6.57%-4.15%-11.98%-24.85%SRPTSarepta Therapeutics0.00%-44.50%-47.02%-73.69%-87.51%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationRNAAvidity Biosciences2.3389 of 5 stars4.50.00.00.03.20.80.0SRPTSarepta Therapeutics4.5427 of 5 stars4.22.00.04.21.51.71.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceRNAAvidity Biosciences 3.06Buy$66.56128.34% UpsideSRPTSarepta Therapeutics 2.46Hold$67.64258.45% UpsideCurrent Analyst Ratings BreakdownLatest RNA and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/20/2025SRPTSarepta TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$123.00 ➝ $45.006/20/2025SRPTSarepta TherapeuticsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform6/18/2025SRPTSarepta TherapeuticsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$85.00 ➝ $40.006/18/2025SRPTSarepta TherapeuticsTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Hold$24.006/17/2025RNAAvidity BiosciencesWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.006/17/2025SRPTSarepta TherapeuticsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$50.00 ➝ $25.006/17/2025SRPTSarepta TherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$29.006/17/2025SRPTSarepta TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$60.00 ➝ $30.006/17/2025SRPTSarepta TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$100.00 ➝ $75.006/17/2025SRPTSarepta TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$89.00 ➝ $29.006/17/2025SRPTSarepta TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoveragePeer Perform(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookRNAAvidity Biosciences$10.90M322.31N/AN/A$11.94 per share2.44SRPTSarepta Therapeutics$1.90B0.98$2.29 per share8.24$15.99 per share1.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateRNAAvidity Biosciences-$322.30M-$3.00N/AN/AN/A-4,136.00%-26.96%-24.57%8/8/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$2.69N/A1.72N/A-11.12%-14.88%-5.12%8/6/2025 (Estimated)Latest RNA and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025RNAAvidity Biosciences-$0.88-$0.90-$0.02-$0.90$2.63 million$1.60 million5/6/2025Q1 2025SRPTSarepta Therapeutics$2.20-$3.42-$5.62-$4.60$685.75 million$744.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthRNAAvidity BiosciencesN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioRNAAvidity BiosciencesN/A16.9116.91SRPTSarepta Therapeutics1.004.022.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipRNAAvidity BiosciencesN/ASRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipRNAAvidity Biosciences3.83%SRPTSarepta Therapeutics7.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableRNAAvidity Biosciences190120.52 million115.90 millionOptionableSRPTSarepta Therapeutics1,37298.28 million90.71 millionOptionableRNA and SRPT HeadlinesRecent News About These CompaniesINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTJune 23 at 11:53 AM | globenewswire.comSRPT FRAUD ALERT: Sarepta Therapeutics, Inc. ...June 22 at 10:00 AM | gurufocus.comSRPT FRAUD ALERT: Sarepta Therapeutics, Inc. Investors are Reminded of Ongoing Securities Fraud Investigation -- Contact BFA Law (NASDAQ:SRPT)June 22 at 9:33 AM | globenewswire.comSarepta Therapeutics (NASDAQ:SRPT) Earns "Market Perform" Rating from William BlairJune 22 at 1:13 AM | americanbankingnews.comSarepta Therapeutics (SRPT) Faces Setback Amid Gene Therapy ConcernsJune 21 at 5:49 PM | gurufocus.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $45.00 at OppenheimerJune 21 at 1:57 AM | americanbankingnews.comWilliam Blair Downgrades Sarepta Therapeutics (SRPT)June 20 at 3:27 PM | msn.comAnalyst Downgrades Sarepta As Elevidys Safety Clouds Future DemandJune 20 at 2:10 PM | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Given New $45.00 Price Target at OppenheimerJune 20 at 11:08 AM | marketbeat.comThis Sarepta Therapeutics Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For FridayJune 20 at 11:05 AM | benzinga.comSRPT INQUIRY: Sarepta Therapeutics, Inc. Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law (NASDAQ:SRPT)June 20 at 9:08 AM | globenewswire.comSarepta Therapeutics (NASDAQ:SRPT) Given "Market Perform" Rating at William BlairJune 20 at 8:29 AM | marketbeat.comTD Cowen Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to HoldJune 20 at 2:29 AM | americanbankingnews.comWhat’s next for Sarepta Therapeutics with gene therapy under fire?June 19, 2025 | statnews.comDeutsche Bank Aktiengesellschaft Issues Pessimistic Forecast for Sarepta Therapeutics (NASDAQ:SRPT) Stock PriceJune 19, 2025 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Rating Lowered to Hold at The Goldman Sachs GroupJune 19, 2025 | americanbankingnews.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Lowered to $75.00 at Wells Fargo & CompanyJune 19, 2025 | americanbankingnews.comSarepta Therapeutics Target of Unusually High Options Trading (NASDAQ:SRPT)June 19, 2025 | americanbankingnews.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc. - SRPTJune 18, 2025 | globenewswire.comSarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences (SRPT)June 18, 2025 | marketbeat.comMizuho Lowers Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $40.00June 18, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRNA and SRPT Company DescriptionsAvidity Biosciences NASDAQ:RNA$29.15 -0.16 (-0.55%) Closing price 04:00 PM EasternExtended Trading$29.29 +0.14 (+0.48%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.Sarepta Therapeutics NASDAQ:SRPT$18.87 -1.21 (-6.03%) Closing price 04:00 PM EasternExtended Trading$19.23 +0.36 (+1.88%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft Stock Holds Steady as AI Drives Workforce Shift Top International ETFs With Dividends and Market-Beating Returns D-Wave Goes International With South Korea Partnership BigBear.ai Poised to Benefit as Palantir Dominates AI Defense Kroger Stock Confirms Buy Signal as Uptrend Gains Strength Darden Stock Set to Sizzle After Blowout Q4 and $1B Buyback Alphabet’s Comeback: The Hidden Engines Powering Google New All-Time Highs Coming for Broadcom? Wall Street Says Yes Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
